	US 12,280,146 B2
	Nanoemulsion without propylene glycol
Montserrat Foguet, Leverkusen (DE); and Lars Möllmann, Leverkusen (DE)
Assigned to Biofrontera Bioscience GmbH, Leverkusen (DE)
Filed by Biofrontera Bioscience GmbH, Leverkusen (DE)
Filed on Dec. 8, 2023, as Appl. No. 18/533,497.
Claims priority of application No. PCT/EP2023/059291 (WO), filed on Apr. 6, 2023.
Prior Publication US 2024/0335380 A1, Oct. 10, 2024
Int. Cl. A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 41/00 (2020.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01)

CPC A61K 9/1075 (2013.01) [A61K 9/127 (2013.01); A61K 41/0061 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)]

17 Claims

1. A formulation comprising:

(a) a nanoemulsion comprising:

(i) at least one aqueous component;

(ii) a carrier component comprising:

(1) at least one lipophilic component,

(2) at least one surfactant, and

(3) at least one alcohol; and

(b) 5-aminolevulinic acid and/or a derivative, a precursor, a metabolite, and/or a pharmaceutically acceptable salt thereof,

wherein the formulation comprises essentially no propylene glycol and essentially no sorbitol.